Medtronic (NYSE:MDT) recently posted its Q1 FY19 numbers, which were better than street estimates, led by a strong growth in the diabetes business. The company also revised its guidance upward, and expects strong growth in diabetes for the full year. We currently forecast a 5% growth in overall...
Medtronic (NYSE:MDT) recently posted its Q1 FY19 numbers, which were better than street estimates, led by a strong growth in the diabetes business. The company also revised its guidance upward, and expects strong growth in diabetes for the full year. We currently forecast a 5% growth in overall...
Share this Article
Recommended